NEO
HOLD / NEUTRALTrendComposite
56.70
Technical
68.80
Fundamental
41.90
Rank
—
Price
17.99
Hurst
0.66
As of
Oct 29, 2026
Daily
NeoGenomics, Inc.
HealthcareDiagnostics & ResearchNeoGenomics operates diagnostic laboratories specializing in cancer testing across the United States and United Kingdom. The company provides various laboratory services to healthcare providers, research institutions, and pharmaceutical firms, including chromosomal analysis, genetic sequencing, cell characterization, protein detection, and microscopic cell examination. Its testing capabilities support both clinical diagnosis and pharmaceutical development programs in oncology.
Market cap
$2.2B
P/E (trailing)
—
P/E (forward)
53.55
PEG ratio
2.09
Dividend yield
0.00%
Beta
1.78
52w range
7.07 – 20.15
Return on equity
-3.94%
Profit margin
-4.10%
Revenue growth
+11.40%
Earnings growth
—
Price history
1Y: 17.38 (+77.9%) · range 7.19–19.91
Cycle position
54/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 14 · NOT READY · exit proximity 0
Conviction
39/ 100 · maturity 100%
VScore.4031
Buildup.2081
EMA entry setup.2514
Fundamentals.1542
Volume profile
POC
14.52
Price vs POC
+19.7%
Overhead supply
22%
Runway
open sky
Value area 13.69–19.67 · 22% of 120d volume overhead · moderate overhead
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.933 | Oct 30, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +13.75% | +13.75% | mature |
| 40d | +28.09% | +30.39% | mature |